Close Menu

Lineagen

The Center for Autism and Related Disorders, a provider of early intensive behavioral intervention for individuals with autism spectrum disorder, will now offer Lineagen's FirstStepDx test as a service to CARD patients and their families.

NEW YORK (GenomeWeb News) – The Center for Autism and Related Disorders and molecular diagnostics firm Lineagen today announced a partnership to offer the FirstStep genetic test to patients.

This story was originally posted on May 17.
Lineagen plans to launch an upgraded version of its FirstStepDx test for autism spectrum disorders.

NEW YORK (GenomeWeb News) – Agilent Technologies this week said that its board of directors has declared a quarterly dividend of $.10 per share payable on July 25 to all shareholders of record as of July 3.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Molecular diagnostics firm Lineagen and Fast Forward have forged a partnership to fund the development of a blood-based assay for multiple sclerosis.

Lineagen's new chromosomal microarray testing and genetic-counseling service, dubbed FirstStepDx, aims to appeal to pediatricians who are charged with treating children with possible autism spectrum disorder or developmental delay.

The newly raised $5 million brings the total Series A round amount to $10.8 million, which the company will use to develop its autism program and support its planned commercial service launch in September.

Pages

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.